MedCap AB (SE:MCAP)
:MCAP
Want to see SE:MCAP full AI Analyst Report?
MCAP Stock Chart & Stats
kr533.00
-kr4.00(-1.07%)
At close: 4:00 PM EST
kr533.00
-kr4.00(-1.07%)
Day’s Range― - ―
52-Week Rangekr376.00 - kr677.00
Previous CloseN/A
Volume7.13K
Average Volume (3M)21.82K
Market Cap
kr7.67B
Enterprise Valuekr8.09B
Total Cash (Recent Filing)kr370.40M
Total Debt (Recent Filing)kr707.00M
Price to Earnings (P/E)31.9
Beta0.63
Next Earnings
Apr 29, 2026EPS Estimate
4.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.79
Shares Outstanding15,077,583
10 Day Avg. Volume14,106
30 Day Avg. Volume21,821
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)22.37
Revenue Forecast (FY)kr2.30B
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue ScalingSustained top-line expansion demonstrates successful acquisition and organic growth execution in niche healthcare segments. A larger revenue base supports operational leverage, resilience to single-period shocks, and the ability to invest in sales coverage and product development over the medium term.
Consistent Operating ProfitabilityStable mid-teens EBIT margins across scaling operations indicate durable unit economics and effective cost management in MedCap's subsidiaries. Persistent profitability underpins internal cash generation, capacity for reinvestment and supports long-term returns from the buy-and-build strategy.
Positive And Growing Free Cash FlowConsistent positive FCF that has grown materially provides funding for acquisitions, capex and upstreaming cash to the parent without relying solely on external financing. Alignment with net income suggests sustainable cash conversion when seasonal or working-capital swings normalize.
Bears Say
Rising Leverage In 2025A notable step-up in debt reduces balance-sheet flexibility and increases interest and refinancing exposure. For an acquisitive healthcare investor, higher leverage constrains the pace of add-on deals, raises covenant risk, and could pressure discretionary investment during industry headwinds.
Inconsistent Cash ConversionRecurring periods where operating cash flow lags earnings point to working-capital volatility or timing gaps in collections. This undermines the reliability of reported profits as a source of reinvestment or dividends and increases reliance on external funding in tighter liquidity scenarios.
Gross-margin Volatility In 2025A material drop in gross margin signals potential structural issues—mix shifts, pricing pressure, or cost inflation—that can erode long-term profitability. If persistent, margin deterioration would limit cash flow upside and require strategic responses (pricing, cost reductions, or product repricing).
MedCap AB News
MCAP FAQ
What was MedCap AB’s price range in the past 12 months?
MedCap AB lowest stock price was kr376.00 and its highest was kr677.00 in the past 12 months.
What is MedCap AB’s market cap?
MedCap AB’s market cap is kr7.67B.
When is MedCap AB’s upcoming earnings report date?
MedCap AB’s upcoming earnings report date is Apr 29, 2026 which is in 10 days.
How were MedCap AB’s earnings last quarter?
MedCap AB released its earnings results on Feb 06, 2026. The company reported kr4.79 earnings per share for the quarter, beating the consensus estimate of kr4.755 by kr0.035.
Is MedCap AB overvalued?
According to Wall Street analysts MedCap AB’s price is currently Overvalued.
Does MedCap AB pay dividends?
MedCap AB does not currently pay dividends.
What is MedCap AB’s EPS estimate?
MedCap AB’s EPS estimate is 4.67.
How many shares outstanding does MedCap AB have?
MedCap AB has 15,077,583 shares outstanding.
What happened to MedCap AB’s price movement after its last earnings report?
MedCap AB reported an EPS of kr4.79 in its last earnings report, beating expectations of kr4.755. Following the earnings report the stock price went up 9.567%.
Which hedge fund is a major shareholder of MedCap AB?
Currently, no hedge funds are holding shares in SE:MCAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedCap AB
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe. It typically invests between SEK25 million ($2.75 million) to SEK150 million ($16.51 million) with enterprise value and sales revenue between SEK50 million ($5.90 million) to SEK200 million ($23.06 million) and EBITDA between SEK1 million ($0.11 million) to SEK50 million ($5.50 million). The firm seeks to acquire stakes between 20% and 50% in its portfolio companies. It uses its capital and loans and makes balance sheet investments. MedCap AB (publ) was founded in 2001 and is based in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---